Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Oncology Adjuvants Market?
The value of the oncology adjuvants market has noticeably increased in recent times. It is predicted to expand from $1.59 billion in 2024 to $1.73 billion in 2025, showing a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth during the historic period include rising cancer rates globally, a higher demand for improved preclinical predictability, more use of patient-derived xenograft (PDX) models, an increased dependency on in vivo efficacy data, and a heightened focus on the early-stage of immuno-oncology.
The market for oncology adjuvants is set to experience robust growth in the coming years, projecting to reach $2.35 billion by 2029 with a compound annual growth rate (CAGR) of 8.0%. This predicted growth during the forecast period can be traced back to factors such as heightened focus on models relevant to human beings, increased demand for precision in oncology, a surge in immuno-oncology treatments, rising demand for high-throughput screening models, and a growing interest in models for rare cancers. The industry trends expected during the forecast period include the incorporation of nanotechnology, enhancement of CAR-T cell therapies by adjuvants, developments in immuno-oncology adjuvants, further enhancement of CAR-T cell therapies by adjuvants, and the application of artificial intelligence and machine learning.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27370&type=smp
Which Factor Is Shaping The Future Of The Oncology Adjuvants Market?
The surge in need for personalized medicine is anticipated to fuel the oncology adjuvants market’s expansion. Personalized medicine, a model that uses an individual’s genetic information and lifestyle environment to custom tailor healthcare and treatments, is on the rise due to advances in genetic and molecular profiling. These advancements allow for the development of therapies specific to a person’s unique biological composition, enhancing effectiveness while decreasing unwanted side effects. Oncology adjuvants contribute to personalized medicine by facilitating the tailoring of additional cancer treatments based on a patient’s distinctive genetic composition and tumor traits. This ensures therapies efficiently target any remaining cancer cells and helps to avoid unnecessary side effects. For example, in February 2023, the Personalized Medicine Coalition, a professional membership organization based in the US, reported that in 2022, the sanctioning of 12 new personalized medicines accounted for roughly 34% of all newly sanctioned therapies, a notable rise from prior years. Hence, the escalating demand for personalized medicine serves as a catalyst for the growth of the oncology adjuvants market.
What Is The Segment-Wise Breakdown Of The Oncology Adjuvants Market?
The oncology adjuvants market covered in this report is segmented
1) By Type Of Adjuvant: Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants
2) By Administration Route: Oral, Intravenous, Subcutaneous, Topical, Intramuscular
3) By Indication: Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications
4) By End User: Cancer Research Institute, Cancer Hospitals
Subsegments:
1) By Chemotherapy Adjuvants: Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others
2) By Radiation Adjuvants: Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation
3) By Immunotherapy Adjuvants: Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents
4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators
5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors
Which Trends Are Redefining The Future Landscape Of The Oncology Adjuvants Industry?
Leading entities in the oncology adjuvants market are concentrating on the fabrication of innovative solutions such as immune checkpoint inhibitor adjuvant therapy. This strategy is aimed at augmenting the effectiveness of post-operative treatments and elevating the overall survival rates of patients by using the immune system to attack remnants of tumor cells. The therapy employs drugs that inhibit immune checkpoint proteins like PD-1, PD-L1 or CTLA-4 which usually serve to control the immune system’s activity. One example of this is the release, in January 2023, by US pharmaceutical firm, Merck & Co., Inc. of KEYTRUDA (pembrolizumab), an approved adjuvant treatment by the Food and Drug Administration (FDA). The therapy, which is used after surgical resection and platinum-based chemotherapy, is intended for patients suffering from Stage IB (T2a=4 centimeters), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) works by blocking the PD-1 receptor, thus rejuvenating the immune system’s power to identify and combat cancer cells. It offers a potent post-operative treatment for patients with non-small cell lung cancer (NSCLC), reducing the chances of cancer relapsing and enhancing overall survival rates. Moreover, KEYTRUDA amplifies personalized cancer treatment by optimizing the patient’s immune response, rendering it an invaluable asset in contemporary immuno-oncology.
Which Companies Hold The Largest Market Share In The Oncology Adjuvants Sector?
Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, SEPPIC, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Aurorium, Elicio Therapeutics Inc.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/oncology-adjuvants-global-market-report
How Does Regional Performance Compare Across The Oncology Adjuvants Industry?
North America was the largest region in the oncology adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27370&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model